Neuromyelitis Optica and Anti-MOG Disease Poster Presentation

P0762 - What percentage of AQP4-Ab-negative NMOSD patients are MOG-Ab positive? A study from the Argentinean multiple sclerosis registry (RelevarEM) (ID 1033)

Speakers
  • E. Carnero Contentti
Authors
  • E. Carnero Contentti
  • P. Lopez
  • J. Pettinicchi
  • A. Pappolla
  • J. Miguez
  • L. Patrucco
  • E. Cristiano
  • C. Vrech
  • V. Tkachuk
  • S. Liwacki
  • J. Correale
  • M. Marrodan
  • M. Gaitán
  • M. Fiol
  • L. Negrotto
  • M. Ysrraelit
  • M. Burgos
  • F. Leguizamon
  • D. Tavolini
  • N. Deri
  • M. Balbuena
  • C. Mainella
  • G. Luetic
  • P. Blaya
  • J. Hryb
  • M. Menichini
  • A. Alves Pinheiro
  • P. Nofal
  • G. Zanga
  • A. Barboza
  • I. Martos
  • L. Lazaro
  • E. Silva
  • S. Bestoso
  • M. Fracaro
  • A. Carra
  • O. Garcea
  • N. Fernandez Liguori
  • M. Alonso Serena
  • A. Caride
  • J. Rojas
Presentation Number
P0762
Presentation Topic
Neuromyelitis Optica and Anti-MOG Disease

Abstract

Background

Myelin oligodendrocyte glycoprotein antibodies (MOG-Ab) have been described in aquaporin-4-antibodies(AQP4-Ab)-negative neuromyelitis optica spectrum disorders (NMOSD) patients.

Objectives

We aimed to investigate the percentage of AQP4-Ab-negative NMOSD patients who are positive for MOG-Ab included in the Argentinean MS and NMOSD registry (RelevarEM, NCT 03375177).

Methods

RelevarEM is a longitudinal, strictly observational multiple sclerosis (MS) and NMOSD registry in Argentina. Epidemiological, serological test and neuroimaging (MRI) data from NMOSD were described.

Results

A total of 165 patients (79 AQP4-Ab positive, 67 AQP4-Ab negative and 19 unknown) were included. Of these, 155 patients fulfilled the 2015 NMOSD diagnostic criteria. Of 67 AQP4-Ab-negative patients, 36 were tested for MOG-Ab and 10 of them (31.8%) tested positive. Presence of relapses during the previous 6 months (40% vs. 12.9%), shorter disease duration (3.9 vs. 7.5 years), lower disability (2.3 vs. 3.4) and treatment duration (1.5 vs. 3.4 years) and both optic neuritis (90% vs. 44.5%) and optic nerve lesion on MRI (80% vs. 25.1%) were significantly associated with MOG-Ab-positive compared with NMOSD respectively

Conclusions

This is the first study of the longitudinal Argentinean registry of MS and NMOSD describing and comparing diseases that contributes to provide reliable real-world data in the country. We observed that 31.8% (10/36) of the AQP4-ab-negative patients tested for MOG-Ab were positive for this antibody, in line with results from other world regions.

Collapse